Skip to main content
. 2023 Nov 27;66:102334. doi: 10.1016/j.eclinm.2023.102334

Fig. 2.

Fig. 2

(A) The composite endpoint, defined as CV death or hospitalisation for CV events in a two-year observation. Log-rank test: p = 0.023 between the dapagliflozin and control groups. (B) Hospitalisation for CV events in a two-year observation. Log-rank test: p = 0.023 between the dapagliflozin and control groups. (C) Hospitalisation for HF in a two-year observation. Log-rank test: p = 0.09 between the dapagliflozin and control groups. (D) Hospitalisation for all causes in a two-year observation. Log-rank test: p = 0.039 between the dapagliflozin and control groups. (E) An additional change in prescriptions for HF in a two-year observation. Log-rank test: p < 0.001 between the dapagliflozin and control groups. (F) New-onset atrial fibrillation and/or atrial flutter in a two-year observation. Log-rank test: p = 0.58 between the dapagliflozin and control groups.